Idhifa

A drug used to treat acute myeloid leukemia (AML) that has recurred (come back) or has not gotten better after treatment with other anticancer therapy. It is used in patients whose cancer has a mutated (changed) form of a gene called isocitrate dehydrogenase-2 (IDH2). It is also being studied in the treatment of other types of cancer. Idhifa blocks the protein made by the mutated IDH2 gene. Blocking this protein may help keep cancer cells from growing. Idhifa is a type of enzyme inhibitor and a type of targeted therapy. Also called enasidenib mesylate.